Subgenotyping and genetic variability of hepatitis C virus in Palestine


Autoři: Sahar Rayan Da’as aff001;  Maysa Azzeh aff001
Působiště autorů: Virology Research Laboratory, Medical Research Center, Al-Quds University, Abu Dies-East Jerusalem, West Bank, Palestine aff001
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0222799

Souhrn

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Genotyping of HCV is crucial for successful therapy. To determine the HCV subgenotypes circulating in Palestine and to study the genetic variability of their core, we collected 84 serum samples which had tested positive for anti-HCV antibodies. Thirty-seven of these samples came from hemodialysis patients. Serum samples were subjected to viral RNA isolation and amplification of the HCV core gene. Thirty-three of the samples (39%) tested positive for HCV RNA. The HCV subgenotypes circulating in Palestine included 1a, 3a, and 4a, detected in 38%, 25%, and 22% of the samples, respectively. Furthermore, subgenotype 1b was present in three samples (9%), while the rare subgenotype 4v was present in two samples (6%). We identified a number of substitutions in the retrieved HCV core sequences, such as HCV 1b substitutions R70Q and M91L, which some studies have associated with hepatocellular carcinoma risk and poor virological response. In contrast to two previous studies reporting that HCV genotype 4 was predominant in the Gaza strip (present in just over 70% of samples), genotype 4 was detected in only 31% of the samples in our current study, whereas genotype 1 and 3 were present in 69% of samples. These differences may relate to the fact that many of our samples came from the West Bank and East Jerusalem. The co-circulation of different HCV genotypes and subgenotypes in Palestine suggests that subgenotyping prior to treatment is crucial in Palestinian patients.

Klíčová slova:

DNA sequence analysis – Egypt – Hepatitis C virus – Medical dialysis – Phylogenetic analysis – Renal transplantation – Sequence alignment – Palestinian territories


Zdroje

1. WHO. Global hepatitis report, 2017 [WHO Report]. 2017. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.

2. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91. doi: 10.1016/s0140-6736(99)06527-7 10752705.

3. WHO. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection 2018. Available from: https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/.

4. Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45–53. doi: 10.1111/liv.13186 27275625; PubMed Central PMCID: PMC5145777.

5. AASLD-IDSA. HCV Guidance: Recommendations forTesting, Managing, and Treating Hepatitis C:; 2018 [updated May 24. 2018; cited 2019]. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018b.pdf.

6. EASL. EASL Recommendation on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018;69:461–511. doi: 10.1016/j.jhep.2018.03.026 29650333

7. Ayesh BM, Zourob SS, Abu-Jadallah SY, Shemer-Avni Y. Most common genotypes and risk factors for HCV in Gaza strip: a cross sectional study. Virol J. 2009;6:105. doi: 10.1186/1743-422X-6-105 19607718; PubMed Central PMCID: PMC2716328.

8. Shemer-Avni Y, el Astal Z, Kemper O, el Najjar KJ, Yaari A, Hanuka N, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. J Med Virol. 1998;56(3):230–3. doi: 10.1002/(sici)1096-9071(199811)56:3<230::aid-jmv9>3.0.co;2-8 9783690.

9. Lole KS, Jha JA, Shrotri SP, Tandon BN, Prasad VG, Arankalle VA. Comparison of hepatitis C virus genotyping by 5' noncoding region- and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India. J Clin Microbiol. 2003;41(11):5240–4. doi: 10.1128/JCM.41.11.5240-5244.2003 14605173; PubMed Central PMCID: PMC262521.

10. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2005;21(3):379–84. Epub 2004/09/21. doi: 10.1093/bioinformatics/bth485 15377502.

11. Nguyen LT, Dunford L, Freitas I, Holder P, Nguyen LA, O'Gorman J, et al. Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen. J Clin Microbiol. 2015;53(8):2697–700. doi: 10.1128/JCM.01062-15 25994168; PubMed Central PMCID: PMC4508445.

12. Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H, et al. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol. 2012;50(6):1943–9. doi: 10.1128/JCM.00487-12 22495557; PubMed Central PMCID: PMC3372108.

13. Budkowska A, Kakkanas A, Nerrienet E, Kalinina O, Maillard P, Horm SV, et al. Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection. PLoS One. 2011;6(1):e15871. doi: 10.1371/journal.pone.0015871 21283512; PubMed Central PMCID: PMC3017048.

14. Korba B, Shetty K, Medvedev A, Viswanathan P, Varghese R, Zhou B, et al. Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk. J Gen Virol. 2015;96(9):2928–37. doi: 10.1099/jgv.0.000219 26296571; PubMed Central PMCID: PMC4857454.

15. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009;100(12):2465–8. doi: 10.1111/j.1349-7006.2009.01338.x 20175782.

16. Fishman SL, Factor SH, Balestrieri C, Fan X, Dibisceglie AM, Desai SM, et al. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res. 2009;15(9):3205–13. doi: 10.1158/1078-0432.CCR-08-2418 19383824; PubMed Central PMCID: PMC3142862.

17. El-Shamy A, Pendleton M, Eng FJ, Doyle EH, Bashir A, Branch AD. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Sci Rep. 2016;6:27025. doi: 10.1038/srep27025 27246310; PubMed Central PMCID: PMC4887904.

18. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007;46(5):1357–64. doi: 10.1002/hep.21836 17657816.

19. Jaspe RC, Sulbaran YF, Sulbaran MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virol J. 2012;9:214. doi: 10.1186/1743-422X-9-214 22995142; PubMed Central PMCID: PMC3511240.

20. Alhamlan FS, Al-Ahdal MN, Khalaf NZ, Abdo AA, Sanai FM, Al-Ashgar HI, et al. Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. J Transl Med. 2014;12:91. doi: 10.1186/1479-5876-12-91 24708767; PubMed Central PMCID: PMC4012185.

21. Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon. 2016;16(9):e40357. doi: 10.5812/hepatmon.40357 27826320; PubMed Central PMCID: PMC5097177.

22. Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2017. doi: 10.1002/jmv.24921 28842995.

23. Sharara AI, Ramia S, Ramlawi F, Fares JE, Klayme S, Naman R. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. Epidemiol Infect. 2007;135(3):427–32. Epub 2006/07/20. doi: 10.1017/S0950268806006911 16848924; PubMed Central PMCID: PMC2870582.

24. Alfaresi MS. Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients. Mol Biol Rep. 2011;38(4):2719–22. Epub 2010/11/26. doi: 10.1007/s11033-010-0415-5 21104026.

25. Kartashev V, Doring M, Nieto L, Coletta E, Kaiser R, Sierra S, et al. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016;81:82–9. doi: 10.1016/j.jcv.2016.05.010 27367545.

26. Kabakci Alagoz G, Karatayli SC, Karatayli E, Celik E, Keskin O, Dinc B, et al. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. Turk J Gastroenterol. 2014;25(4):405–10. Epub 2014/09/26. doi: 10.5152/tjg.2014.7083 25254523.

27. Ezzikouri S, Pineau P, Benjelloun S. Hepatitis C virus infection in the Maghreb region. J Med Virol. 2013;85(9):1542–9. Epub 2013/06/20. doi: 10.1002/jmv.23643 23780703.

28. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol. 2005;43(4):1902–9. Epub 2005/04/09. doi: 10.1128/JCM.43.4.1902-1909.2005 15815016; PubMed Central PMCID: PMC1081338.

29. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, et al. Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. J Med Virol. 2009;81(6):1015–23. Epub 2009/04/22. doi: 10.1002/jmv.21492 19382263.

30. Janahi EM, Al-Mannai M, Singh H, Jahromi MM. Distribution of Hepatitis C Virus Genotypes in Bahrain. Hepat Mon. 2015;15(12):e30300. Epub 2016/03/16. doi: 10.5812/hepatmon.30300 26977163; PubMed Central PMCID: PMC4774338.

31. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48(6):372–80. doi: 10.1159/000086064 16024941.

32. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81(15):8211–24. doi: 10.1128/JVI.00487-07 17522222; PubMed Central PMCID: PMC1951276.

33. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421–9. Epub 2010/07/22. doi: 10.1002/hep.23690 20648473.

34. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol. 2011;83(6):1016–22. doi: 10.1002/jmv.22094 21503914.

35. Akuta N, Suzuki F, Kobayashi M, Sezaki H, Kawamura Y, Hosaka T, et al. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol. 2015;53(9):3039–41. Epub 2015/07/03. doi: 10.1128/JCM.01457-15 26135874; PubMed Central PMCID: PMC4540910.

36. Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, et al. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance. J Clin Microbiol. 2019;57(1). Epub 2018/11/02. doi: 10.1128/JCM.01463-18 30381417; PubMed Central PMCID: PMC6322466.

37. Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, et al. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. J Med Virol. 2018;90(6):1087–93. Epub 2018/02/11. doi: 10.1002/jmv.25047 29427443.


Článek vyšel v časopise

PLOS One


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se